Astraveus Enhances Leadership Structure Ahead of Major Product Launch

Astraveus SAS, the pioneer in the development of the Benchtop Cell Factory, recently announced significant enhancements to its leadership team and Board of Directors. With the appointment of three seasoned professionals, the company is poised to accelerate progress and prepare for the imminent launch of its innovative Lakhesys Benchtop Cell Factory.

New Appointments and Expertise

Jean-Paul Mangeolle as Chairman

Jean-Paul Mangeolle, who brings over 35 years of experience in the life sciences sector, has stepped in as the new Chairman of the Board of Directors. His extensive background includes holding key roles at major industry players like Millipore and Danaher. His leadership will be instrumental as Astraveus navigates its transformative growth phase.

David Newble Joins as Independent Board Member

David Newble, a well-respected figure in life sciences technology, joins the board as an independent member. With previous leadership roles at SPT Labtech and TAP Biosystems, he played a crucial part in the development of the Ambr® bioreactor portfolio. His insight and experience will undoubtedly contribute greatly to Astraveus's strategic direction, particularly in advancing its commitment to the cell therapy market.

Laurence Riot Lamotte, CFO

Laurence Riot Lamotte joins Astraveus as Chief Financial Officer, bringing a wealth of financial acumen that spans three decades, primarily within the life sciences sector. Previously the CFO of Evexta Bio, her knowledge of the financial landscape in biotechnology will be crucial in guiding Astraveus through its next growth milestones. Laurene is particularly excited about enhancing the accessibility of cell therapy technologies through strategic financing solutions.

The Importance of These Changes

The internal shifts at Astraveus come at a crucial time when the company is rapidly nearing the launch of its unique Lakhesys Benchtop Cell Factory. This innovative system is set to redefine how cell therapies are manufactured, allowing for both cost reductions and increased efficiency in production processes. With their advanced microfluidic technology, Astraveus aims to optimize and scale biomanufacturing, bringing significant value to the cell therapy industry.

As highlighted by Jérémie Laurent, CEO of Astraveus, this new leadership team is expected to propel the company's initiatives forward. He noted that the combined expertise of Mangeolle, Newble, and Lamotte creates a robust foundation to drive the company's ambitious goals, particularly in commercializing the Lakhesys technology.

Vision for the Future

Jean-Paul Mangeolle articulated his enthusiasm for guiding the company through this transformative phase, emphasizing the strength of Astraveus’s technology in facilitating enhanced process optimization. He expressed excitement about helping the team achieve successful commercialization for the Lakhesys portfolio.

David Newble also underscored the unique positioning of the Lakhesys Benchtop Cell Factory in the evolving cell therapy landscape, noting that it could significantly lead to more mature industry standards and practices.

Laurence Riot Lamotte highlighted a critical area of growth in bioprocessing solutions, especially within cell therapies, emphasizing Astraveus's impressive developmental roadmap. She is committed to leveraging her financial experience to the benefit of the company and the patients who will ultimately benefit from these advancements.

As the global biotechnology landscape continues to evolve, Astraveus is strategically placing itself at the forefront of this change, committed to making cell therapies more effective and accessible. Their new leadership team represents a blend of experience and innovation, suggesting an exciting future for both the company and the industry as a whole.

About Astraveus

Founded in 2016 by Jérémie Laurent within the esteemed environment of Saint-Louis Hospital in Paris, Astraveus is dedicated to revolutionizing the cell therapy manufacturing process. By leveraging cutting-edge microfluidic technology, the company aims to drastically reduce costs while maintaining high-quality production standards, making advanced therapies accessible to those in need.

For more information, visit Astraveus’s official website.